Q32 Bio Inc (QTTB)
NASDAQ:QTTB
Want to see QTTB full AI Analyst Report?
Top Page
Q32 Bio
(NASDAQ:QTTB)
Select Model
Select Model
Rating:50Neutral
Price Target:
$6.00
▲(2.56% Upside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by persistent negative operating/free cash flow and the resulting financing risk despite improved reported profitability and a healthier balance sheet. Technicals are weak-to-neutral (below key moving averages with negative MACD), while valuation signals are not supportive due to a negative P/E and no dividend. Recent capital-raise actions add flexibility but underscore dependence on external funding.
Positive Factors
Improved reported profitability
The company’s TTM operating and net margins expanded sharply, delivering high reported profitability on meaningful revenue. Sustained margins increase internal funding capacity for R&D and trials, improve partner negotiation leverage, and lower near-term reliance on dilutive financing if maintained.
Negative Factors
Persistent negative operating cash flow
Consistent negative operating and free cash flow creates a structural financing need for a clinical-stage biotech. Continued cash burn forces regular capital raises, increases dilution risk, and constrains the company's ability to fund expansion or withstand trial delays without external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved reported profitability
The company’s TTM operating and net margins expanded sharply, delivering high reported profitability on meaningful revenue. Sustained margins increase internal funding capacity for R&D and trials, improve partner negotiation leverage, and lower near-term reliance on dilutive financing if maintained.
Read all positive factors
Q32 Bio (QTTB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$93.26M
Dividend YieldN/A
Average Volume (3M)300.85K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.68
Shares Outstanding16,956,415
10 Day Avg. Volume237,818
30 Day Avg. Volume300,850
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue0.64
Enterprise Value/Gross Profit0.64
Enterprise Value/Ebitda1.55
Forecast
1Y Price Target
$14.25Price Target Upside143.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.83
Revenue Forecast (FY)N/A
Q32 Bio Business Overview & Revenue Model
Company Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead p...
How the Company Makes Money
null...
Q32 Bio Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
72
Positive
Cash Flow
36
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.74M | 53.74M | 0.00 | -6.65M | 6.65M | 33.97M |
| Gross Profit | 53.47M | 53.35M | -487.00K | -6.65M | 6.65M | 24.43M |
| EBITDA | 22.15M | 17.29M | -45.30M | -47.76M | -38.85M | -86.22M |
| Net Income | 33.24M | 29.82M | -47.73M | -53.74M | -42.81M | -95.76M |
Balance Sheet | ||||||
| Total Assets | 63.67M | 61.78M | 92.33M | 47.06M | 61.77M | 211.72M |
| Cash, Cash Equivalents and Short-Term Investments | 50.75M | 48.30M | 77.97M | 25.62M | 43.89M | 155.87M |
| Total Debt | 10.99M | 15.34M | 18.90M | 50.84M | 44.73M | 23.93M |
| Total Liabilities | 17.36M | 19.76M | 86.66M | 229.98M | 192.49M | 42.07M |
| Stockholders Equity | 46.31M | 42.01M | 5.67M | -182.92M | 177.98M | 169.65M |
Cash Flow | ||||||
| Free Cash Flow | -27.40M | -33.54M | -67.79M | -18.68M | -13.44M | -112.15M |
| Operating Cash Flow | -27.40M | -33.54M | -67.72M | -18.68M | -10.96M | -109.75M |
| Investing Cash Flow | 7.00M | 7.00M | 19.93M | -5.00K | -2.47M | -50.79M |
| Financing Cash Flow | 5.67M | -3.13M | 95.14M | 406.00K | 30.07M | 52.17M |
Q32 Bio Technical Analysis
Negative
5.85
Price Trends
6.01
Negative
5.07
Positive
3.74
Positive
Market Momentum
>-0.01
Negative
46.66
Neutral
45.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QTTB, the sentiment is Negative. The current price of 5.85 is above the 20-day moving average (MA) of 5.62, below the 50-day MA of 6.01, and above the 200-day MA of 3.74, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.66 is Neutral, neither overbought nor oversold. The STOCH value of 45.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QTTB.
Q32 Bio Risk Analysis
Q32 Bio disclosed 84 risk factors in its most recent earnings report. Q32 Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Q32 Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $93.26M | -2.97 | 230.68% | ― | ― | ― | |
50 Neutral | $64.75M | -1.14 | -346.03% | ― | ― | 28.53% | |
49 Neutral | $30.65M | -1.49 | -503.79% | ― | ― | 73.56% | |
44 Neutral | $34.66M | -4.61 | -10.61% | ― | ― | 70.83% | |
43 Neutral | $26.80M | -0.16 | -309.60% | ― | ― | 65.65% | |
41 Neutral | $9.95M | 0.41 | -526.36% | ― | ― | 16.33% |
* Healthcare Sector Average
QTTB
Q32 Bio
5.80
4.18
258.02%
TPST
Tempest Therapeutics
1.86
-4.37
-70.14%
PDSB
PDS Biotechnology
1.20
-0.38
-24.05%
GRCE
Grace Therapeutics
2.20
-0.77
-25.93%
CALC
CalciMedica
0.63
-1.17
-65.11%
SNTI
Senti Biosciences
0.99
-2.21
-69.19%
Q32 Bio Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Q32 Bio Expands ATM Offering With New $75M Prospectus
Neutral
Apr 24, 2026
On March 27, 2026, Q32 Bio Inc. entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald Co., enabling at-the-market sales of its common stock under a prospectus supplement for up to $14.2 million. Having now sold the full...
Business Operations and StrategyPrivate Placements and Financing
Q32 Bio Launches Flexible $14.2 Million ATM Program
Positive
Mar 27, 2026
On March 27, 2026, Q32 Bio entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald to establish an at-the-market equity program for its common stock. The arrangement allows the company, at its discretion, to sell up to $14...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.